{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T22:55:05Z","timestamp":1777330505793,"version":"3.51.4"},"reference-count":36,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Photocure ASA, Norway","award":["AGR-2017-713-3965"],"award-info":[{"award-number":["AGR-2017-713-3965"]}]},{"name":"Aarhus University","award":["AGR-2017-713-3965"],"award-info":[{"award-number":["AGR-2017-713-3965"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Repeated transurethral bladder resections (TURBs) and instillation treatments in non-muscle invasive bladder cancer (NMIBC) might influence bladder function and, therefore, quality of life. Bladder-related medication is a surrogate marker of compromised bladder function. The objective was to investigate whether TURBs and adjuvant instillation therapy are associated with the use of anticholinergics, \u03b23-agonists, and cystitis-relevant antibiotics. We divided all Danish patients diagnosed with primary NMIBC during 2002\u20132017 registered in the Danish National Patient Registry (DNPR) based on TURB-load within the first five years from diagnosis (1 TURB, 2\u20134 TURBs, \u22655 TURBs). Instillation therapy with either mitomycin C (MMC) or bacillus Calmette-Guerin vaccine (BCG) was independent exposure (yes or no). We included 17,774 patients; 76% men, median age: 70 years (IQR: 63, 77). Patients exposed to \u22655 TURBs had a higher risk of using bladder-relaxing medication than patients exposed to 1 TURB, HR = 4.01 [3.33; 4.83], and higher risk of cystitis, HR = 2.27 [2.05; 2.51]. BCG-exposed patients had a higher risk of bladder-relaxing medication use compared to non-exposed, HR = 1.92 [1.69; 2.18], and a higher risk of cystitis, HR = 1.39 [1.31; 1.48]. Repeated TURBs have the highest impact on bladder function. Adjuvant instillation therapy is also associated with the use of bladder-related medication.<\/jats:p>","DOI":"10.3390\/cancers16101936","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T03:36:42Z","timestamp":1716176202000},"page":"1936","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Use of Bladder-Related Medication in Non-Muscle Invasive Bladder Cancer Patients"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1378-2673","authenticated-orcid":false,"given":"Linea","family":"Blichert-Refsgaard","sequence":"first","affiliation":[{"name":"Department of Urology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 35, 8200 Aarhus N, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2441-1790","authenticated-orcid":false,"given":"Charlotte","family":"Graugaard-Jensen","sequence":"additional","affiliation":[{"name":"Department of Urology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 35, 8200 Aarhus N, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6110-5891","authenticated-orcid":false,"given":"Mette","family":"N\u00f8rgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Alle 43-45, 8200 Aarhus N, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rgen Bjerggaard","family":"Jensen","sequence":"additional","affiliation":[{"name":"Department of Urology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 35, 8200 Aarhus N, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"(2022, April 22). DaBlaCa-Data Annual Report 2020, Bladder Cancer, Denmark. Available online: https:\/\/www.sundhed.dk\/content\/cms\/86\/15686_dablaca_aarsrapport_2020_offentlig_260221.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)\u20142019 Update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_5","unstructured":"(2022, May 05). DaBlaCa [National Guidelines, Bladder Cancer]. Available online: http:\/\/www.skejby.net\/DaBlaCa-web\/DaBlaCaWEB.htm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2016.05.002","article-title":"Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia","volume":"47","author":"Tan","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/bju.14557","article-title":"Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour","volume":"123","author":"Soria","year":"2019","journal-title":"BJU Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/j.1464-410X.2011.10571.x","article-title":"Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: Validation across time and place and recommendation for benchmarking","volume":"109","author":"Mariappan","year":"2012","journal-title":"BJU Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1464-410X.2005.05404.x","article-title":"Towards a better understanding of involuntary detrusor activity","volume":"95","author":"Bradshaw","year":"2005","journal-title":"BJU Int."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Shang, P.F., Kwong, J., Wang, Z.P., Tian, J., Jiang, L., Yang, K., Yue, Z.J., and Tian, J.Q. (2011). Intravesical Bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst. Rev., Cd006885.","DOI":"10.1002\/14651858.CD006885.pub2"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","article-title":"Side Effects of Bacillus Calmette-Guerin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur.Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1126\/science.287.5462.2398","article-title":"Epidemiology. When an entire country is a cohort","volume":"287","author":"Frank","year":"2000","journal-title":"Science"},{"key":"ref_13","unstructured":"(2022, July 31). DanmarksStatestik Statestikbanken. Available online: http:\/\/extranet.dst.dk\/pyramide\/pyramide.htm#!y=2017&a=16,65&v=2&g."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand. J. Public Health"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: A review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin. Epidemiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2147\/CLEP.S376566","article-title":"Positive Predictive Values of Procedure Codes on the Treatment of Non-Muscle Invasive Bladder Cancer in the Danish National Patient Registry","volume":"14","author":"Bengtsen","year":"2022","journal-title":"Clin. Epidemiol."},{"key":"ref_17","unstructured":"(2022, July 03). Sundhedsdatastyrelsen Landsregistret for Patologi. Available online: https:\/\/www.esundhed.dk\/Dokumentation\/DocumentationExtended?id=18."},{"key":"ref_18","unstructured":"Petersen, A. (2022, July 03). SNOMED-Kodning Af Neoplastiske Bl\u00e6rel\u00e6sioner. Available online: https:\/\/www.patobank.dk\/wp-content\/uploads\/2019\/10\/B._Blaerecancer-2.pdf."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Brierley, J.D., Gospodarowicz, M.K., and Wittekind, C. (2016). TNM Classification of Malignant Tumours, John Wiley & Sons. [8th ed.].","DOI":"10.1002\/9780471420194.tnmc26.pub3"},{"key":"ref_20","first-page":"371","article-title":"Classification of bladder tumours based on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years","volume":"130","author":"Bergkvist","year":"1965","journal-title":"Acta Chir. Scand."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_22","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology (2022, July 03). International Language for Drug Utilization Research. Available online: https:\/\/www.whocc.no\/."},{"key":"ref_23","first-page":"798","article-title":"Data Resource Profile: The Danish National Prescription Registry","volume":"46","author":"Pottegard","year":"2017","journal-title":"Int. J. Epidemiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/CLEP.S9908","article-title":"Existing data sources for clinical epidemiology: The Danish National Pathology Registry and Data Bank","volume":"2","author":"Erichsen","year":"2010","journal-title":"Clin. Epidemiol."},{"key":"ref_25","first-page":"9480","article-title":"Health-related quality of life after BCG or MMC induction for non-muscle invasive bladder cancer","volume":"25","author":"Siracusano","year":"2018","journal-title":"Can. J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: Formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.urolonc.2020.06.013","article-title":"Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review","volume":"38","author":"Mori","year":"2020","journal-title":"Urol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrurol.2016.165","article-title":"Low adherence to guidelines in non-muscle-invasive disease","volume":"13","author":"Burger","year":"2016","journal-title":"Nat. Rev. Urol."},{"key":"ref_29","unstructured":"(2022, April 16). WHO Antimicrobial Resistance. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nrurol.2015.12","article-title":"Quality of life in patients with non-muscle-invasive bladder cancer","volume":"12","author":"Sanchez","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.eururo.2021.01.032","article-title":"Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes","volume":"79","author":"Catto","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1046\/j.1464-410X.1996.00134.x","article-title":"Quality of life in patients undergoing bacille Calmette-Gu\u00e9rin therapy for superficial bladder cancer","volume":"78","author":"Mack","year":"1996","journal-title":"Br. J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3233\/BLC-170138","article-title":"Defining Priorities to Improve Patient Experience in Non-Muscle Invasive Bladder Cancer","volume":"4","author":"Garg","year":"2018","journal-title":"Bladder Cancer"},{"key":"ref_34","first-page":"76.e9","article-title":"Quality of life and adverse events in patients with nonmuscle invasive bladder cancer receiving adjuvant treatment with BCG, MMC, or chemohyperthermia","volume":"39","year":"2021","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.eururo.2020.07.009","article-title":"The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial","volume":"78","author":"Lindgren","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1200\/JCO.22.00470","article-title":"DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial","volume":"41","author":"Lindgren","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/10\/1936\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:44:57Z","timestamp":1760107497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/10\/1936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,20]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["cancers16101936"],"URL":"https:\/\/doi.org\/10.3390\/cancers16101936","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,20]]}}}